Results 11 to 20 of about 362 (158)

Special Issue “Targets, Tracers and Translation Novel Radiopharmaceuticals Boost Nuclear Medicine”

Pharmaceuticals, 2019
This is the fourth Special Issue in Pharmaceuticals within the last six years dealing with aspects of radiopharmaceutical sciences [...]
Gerald Reischl
doaj   +1 more source

Neuroimaging with Radiopharmaceuticals Targeting the Glutamatergic System

CHIMIA, 2020
Radiopharmacy at ETH has worked on the development of novel PET tracers for neuro-, cardiac- and tumor imaging for many years. In this paper, our efforts on targeting the glutamatergic system of the metabotropic glutamate receptor subtype 5 (mGluR5) and ...
Linjing Mu, Stefanie D. Kramer, Hazem Ahmed, Stefan Gruber, Susanne Geistlich, Roger Schibli, Simon M. Ametamey   +6 more
doaj   +1 more source

Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma

BMC Cancer, 2018
Background Protein kinase inhibitors (PKIs) are currently tested in clinical studies (phase I-III) as an alternative strategy against (recurrent) ovarian cancer.
Dennis Lindenblatt, Nastassja Terraneo, Giovanni Pellegrini, Susan Cohrs, Philipp René Spycher, David Vukovic, Martin Béhé, Roger Schibli, Jürgen Grünberg   +8 more
doaj   +1 more source

Evaluation of Actinium-225 Labeled Minigastrin Analogue [²²⁵Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy

Pharmaceutics, 2020
The overexpression of cholecystokinin B receptor (CCKBR) in human cancers led to the development of radiolabeled minigastrin analogues for targeted radionuclide therapy, which aims to deliver cytotoxic radiation specifically to cancer cells.
Yun Qin, Stefan Imobersteg, Alain Blanc, Stephan Frank, Roger Schibli, Martin P. Béhé, Michal Grzmil   +6 more
doaj   +1 more source

Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)

Journal of Hematology & Oncology, 2022
The vast majority of our knowledge regarding cancer radiobiology and the activation of radioresistance mechanisms emerged from studies using external beam radiation therapy (EBRT).
Michal Grzmil, Paul Boersema, Ashish Sharma, Alain Blanc, Stefan Imobersteg, Martin Pruschy, Paola Picotti, Roger Schibli, Martin Behe   +8 more
doaj   +1 more source

Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [¹⁷⁷Lu]Lu-PP-F11N

Pharmaceutics, 2021
The inhibition of the mammalian target of rapamycin complex 1 (mTORC1) by everolimus (RAD001) was recently shown to enhance the tumor uptake of radiolabeled minigastrin.
Michal Grzmil, Stefan Imobersteg, Alain Blanc, Stephan Frank, Roger Schibli, Martin P. Béhé   +5 more
doaj   +1 more source

Science research experience in the use of radiopharmaceuticals at the N.N. Petrov NMRC of Oncology [PDF]

Pharmacy Formulas, 2021
Radionuclide diagnostics and therapy with open radionuclide sources are one of the most promising and fast-growing areas ofmodern oncology. The paper presents the main achievements of the N.N. Petrov National Medical Research Center of Oncology, one of the leading departments of radionuclide diagnostics in Russia.
openaire   +1 more source

Pharmaceuticals—Special Issue on Radiopharmaceutical Chemistry between Imaging and Endoradiotherapy

Pharmaceuticals, 2014
The fields of molecular biology, immunology and genetics have generated many important developments that advance the understanding of the induction and progression of oncological, cardiological and neurological diseases as well as the identification of ...
Klaus Kopka
doaj   +1 more source

Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile

Molecules, 2020
The concept of using ibuprofen as an albumin-binding entity was recently demonstrated by the development of [177Lu]Lu-Ibu-PSMA-01. In the present study, we designed a novel ibuprofen-containing radioligand (Ibu-PSMA-02) with subtle structural changes ...
Luisa M. Deberle, Viviane J. Tschan, Francesca Borgna, Fan Sozzi-Guo, Peter Bernhardt, Roger Schibli, Cristina Müller   +6 more
doaj   +1 more source

Radiosynthesis and preclinical evaluation of [11C]SNX-ab as an Hsp90α,β isoform-selective PET probe for in vivo brain and tumour imaging

EJNMMI Radiopharmacy and Chemistry, 2023
Background The molecular chaperone, Hsp90, is a key player in the protein quality control system that maintains homeostasis under cellular stress conditions.
Romy Cools, Koen Vermeulen, Valeria Narykina, Renan C. F. Leitao, Guy Bormans   +4 more
doaj   +1 more source